BIO3 Share Price

Open 12.96 Change Price %
High 13.12 1 Day 0.18 1.40
Low 12.90 1 Week -1.17 -8.24
Close 13.03 1 Month 0.75 6.11
Volume 11703 1 Year -2.03 -13.48
52 Week High 16.59
52 Week Low 10.31
BIO3 Important Levels
Resistance 2 13.23
Resistance 1 13.15
Pivot 13.02
Support 1 12.91
Support 2 12.83
ETR Germany Most Active Stocks
CBK 6.57 -2.23%
CBK 6.57 -2.23%
DBK 14.94 -1.26%
DBK 14.94 -1.26%
DTE 14.78 0.96%
DTE 14.78 0.96%
DTE 14.78 0.96%
DTE 14.78 0.96%
DTE 14.78 0.96%
EOAN 6.08 -0.16%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
PC6A 71.00 14.52%
5M71 39.00 13.70%
FMV 9.04 10.65%
BEO 3.38 6.96%
PA2 16.45 6.89%
ITN 0.48 6.67%
G6P 3.20 6.31%
T5O 8.80 6.02%
CRZ 1.45 5.84%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
CEW3 0.18 -18.18%
USE 0.21 -12.50%
TIN 0.56 -8.20%
TIN 0.56 -8.20%
TIN 0.56 -8.20%
More..

Biotest AG (ETR: BIO3)

BIO3 Technical Analysis 3
As on 2nd Dec 2016 BIO3 Share Price closed @ 13.03 and we RECOMMEND Sell for LONG-TERM with Stoploss of 13.58 & Sell for SHORT-TERM with Stoploss of 13.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIO3 Target for December
1st Target up-side 14.91
2nd Target up-side 15.97
3rd Target up-side 17.03
1st Target down-side 11.89
2nd Target down-side 10.83
3rd Target down-side 9.77
BIO3 Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotest.de
BIO3 Address
BIO3
Landsteinerstrasse 5
Dreieich, 63303
Germany
Phone: 49 6103 801 4406
Fax: 49 6103 801 347
BIO3 Latest News
Interactive Technical Analysis Chart Biotest AG ( BIO3 ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotest AG
BIO3 Business Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.